Paul K. Audhya Sells 2,187 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,187 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.87, for a total value of $21,585.69. Following the completion of the sale, the insider now owns 97,012 shares in the company, valued at $957,508.44. This represents a 2.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $10.09 on Friday. The firm has a fifty day moving average price of $10.98 and a two-hundred day moving average price of $11.93. KalVista Pharmaceuticals, Inc. has a one year low of $7.39 and a one year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KALV. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Great Point Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the second quarter valued at approximately $15,768,000. Emerald Advisers LLC boosted its position in shares of KalVista Pharmaceuticals by 29.8% in the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in KalVista Pharmaceuticals by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after buying an additional 944 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC increased its position in KalVista Pharmaceuticals by 323.5% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock valued at $807,000 after buying an additional 52,347 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).